The goal ofthe Developmental Research Program ofthe M. D. Anderson Cancer Center Prostate SPORE is to fund promising pilot studies in translational prostate cancer research. As in the initial SPORE, the Developmental Research Program in this new proposal will emphasize the support of translational research studies that can generate clinically testable hypotheses to help us reduce the incidence and mortality of prostate cancer or improve the quality of life of prostate cancer patients. The M. D. Anderson Cancer Center Prostate SPORE Administrative Core will solicit Letters of Intent of no more than two pages for innovative translational research from all institutional investigators, including participants in the SPORE Career Development Program. These applications will be screened by the Program Director and Co-Director as well as the Principal Investigator and Co-Principal Investigator according to objective criteria. Investigators of selected applications will be asked to prepare a five-page proposal modeled after an NIH ROl. As appropriate, the Administrative Core will help investigators submitting proposals to formulate translational specific aims and research plans, as many of these investigators will not have expertise in this area. The process will therefore be a major educational activity and will further stimulate the development of innovative translational research concepts. The proposals will be reviewed and prioritized by the SPORE Leaders (principal Investigators, research project leaders, program directors, and core directors). The projects will be funded for 1 year and will be renewable for an additional year. Developmental Research projects will be evaluated ad hoc and annually by the Program Director/Co-Director, SPORE Leaders, Executive Committee, and the combined Internal/External Advisory Board. Fifteen developmental projects were funded in the initial Prostate SPORE. Investigators receiving Developmental Research grants reported 255 publications related to the research (2001-2006) supported by their grants during 2001-2008. A total of 28 externally reviewed grants were funded. Importantly, two investigators who did not have significant roles in the initial SPORE submission are investigators in major projects or cores in the new Prostate SPORE submission: Drs. Lin (Director, Career Development) and Navone (Leader, Project 4;Special Advisor, Project 3;Collaborator, Core C), highlighting the importance of the Developmental Research Program in identifying projects and investigators with potential value for translational research.
The goal ofthe Developmental Research Program ofthe M. D. Anderson Cancer Center Prostate SPORE is to fund promising pilot studies in translational prostate cancer research that can generate clinically testable hypotheses to help us reduce the incidence and mortality of prostate cancer or improve the quality of life of prostate cancer patients.
|Jin, J-K; Tien, P-C; Cheng, C-J et al. (2015) Talin1 phosphorylation activates ?1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene 34:1811-21|
|Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7|
|Yu, Guoyu; Lee, Yu-Chen; Cheng, Chien-Jui et al. (2015) RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res 13:348-57|
|Al Olama, Ali Amin; Kote-Jarai, Zsofia; Berndt, Sonja I et al. (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46:1103-9|
|Satcher, Robert L; Pan, Tianhong; Cheng, Chien-Jui et al. (2014) Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One 9:e89880|
|Jiang, Xianhan; Li, Xun; Huang, Hai et al. (2014) Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer. Cancer 120:1228-36|
|Tien, Jean Ching-Yi; Liao, Lan; Liu, Yonghong et al. (2014) The steroid receptor coactivator-3 is required for developing neuroendocrine tumor in the mouse prostate. Int J Biol Sci 10:1116-27|
|Li, Likun; Chang, Wenjun; Yang, Guang et al. (2014) Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7:ra47|
|Li, Hongge; Tao, Chenqi; Cai, Zhigang et al. (2014) Frs2* and Shp2 signal independently of Gab to mediate FGF signaling in lens development. J Cell Sci 127:571-82|
|Lin, Zhuo-Yuan; Huang, Ya-Qiang; Zhang, Yan-Qiong et al. (2014) MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer 135:541-50|
Showing the most recent 10 out of 77 publications